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ABSTRACT  
A new, simple, precise, accurate and reproducible Reverse Phase High Performance Liquid Chromatography (RP-HPLC) method for 
Simultaneous estimation of bulk and pharmaceutical formulations. Separation of Mirabegron was successfully achieve , C18, 250X4.6mm, 5µm 
or equivalent in an isocratic mode utilizing methanol water (70:30) at pH 5.0 Adjusted to OPA at a flow rate of 1.0ml/min and eluate was 
monitored at 243nm, with a retention time of 2.584 minutes for Mirabegron. The method was validated and the response was found to be linear 
in the drug concentration range of 50µg/ml to150 µg/ml for Mirabegron. The values of the correlation coefficient were found to 0.999for 
Mirabegron. The Limit of Detection(LOD) and Limit of Quantification (LOQ) for Mirabegron were found to be 0.149 and 0.498 res pectively. This 
method was found to be good percentage recovery were found to be 99 indicates that the proposed method is highly accurate. The specificity of 
the method shows good correlation between retention times of standard with the sample so, the method specifically determines the analyte in 
the sample without interference from excipients of tablet dosage forms. The method was extensively validated according to International 
Council for Harmonisation(ICH) guidelines for Linearity, Accuracy, Precision, Specificity and Robustness.  
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INTRODUCTION  
The chemical name for Mirabegron is 2-(2-amino-1, 3 
thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-
phenylethyl]amino]ethyl]phenyl]acetamide having a 
molecular formula of C21H24N4O2S and a molecular weight 
of 396.509 g/mol.1 Mirabegron is a beta-3 adrenergic 
agonist that is used for treatment of overactive bladder 
syndrome.2-4 It has not been implicated in causing liver 
enzyme elevations or clinically apparent acute liver injury. 
Its primary use is in the treatment of overactive bladder.5 
Mirabegron dose-dependently increased cyclic adenosine 3', 
5'-monophosphate (cAMP) concentrations in bladder tissues 
isolated from rats and showed a potent relaxant effect in 
isolated rat and human bladder strips precontracted with 
carbachol at low contraction tonus. Recently, Mirabegron 
was shown to relax in vitro human and rabbit prostate 
smooth muscle through activation of β3 adrenoceptor. The 
same group also showed that Mirabegron encourages 
smooth muscle relaxation by α1 adrenergic receptor 
blockade. 
 
Fig 1- chemical structure of Mirabegron 
 
Mirabegron is highly soluble in water, sparingly soluble in 
methanol, and practically insoluble in methylene chloride.6 
Analytical method development and validation play 
important role in the discovery, development and 
manufacture of pharmaceuticals.7-8 A detailed literature 
survey reveals that only a few methods are reported 
previously to determine Mirabegron. 
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MATERIAL AND METHODS: 
Apparatus:  
HPLC Water 486 Tunable Absorbance Detector Model No 
HPLC 610 Series Detector UV-visible Software Conquer 
Column C18 (250mm × 4.6mm), 5μm id. filtered using 0.45μ 
membrane filter Nylon 0.45μ and ultra-sonicated Model: 
WUC 4L Capacity. 
 Chemicals and solvents: 
Mirabegron drug were perches from MSN Laboratory Ltd 
Hyderabad the marketed formulation of Mirabegron OAB-F ( 
Alembic Pharmaceutical LTD) were perches from local 
market  HPLC  grade  water,  methanol  were  purchased  
from E.MerckLtd., Mumbai,India. 
Chromatographic condition: 
Column :  Grace  C18  (4.6  ID×250 mm;5μm) column, Mobile 
phase: Methanol: water (70:30) at pH 5.0 adjusted with OPA 
Flow Rate:  1.0 ml/min, Detection  Wavelength:243  nm,  Run  
time: 6 min,  Injection volume: 20.0 μl. 
 Detection Wavelength by UV Spectroscopy: 
The absorption maximum of MGN was determined using 
10μg/ml working solution of MGN. The solution was 
prepared in mobile phase (Methanol 70:Water 30 at pH 
5.0adjusted with OPA). The absorption spectrum or UV 
spectrum recorded for MGN was as shown in Figure 2 and 
the corresponding absorbance values were as illustrated in 
Table 1. As shown in Table 1, the MGN has showed 
absorbance at two different wavelength viz. 243 and 204nm. 
Out of the two wavelengths, the absorbance at 204nm was 
found to be 1.114 which found maximum of the two 
absorbances. Nevertheless, it is in the range of solvent cutoff 
for Methanol. As Methanol is component of the mobile phase, 
the other wavelength 243nm with absorbance of 0.773, 
although less than that at 204nm was selected for further 
analysis in order to avoid interferences of mobile Phase
  
 
Fig 2: UV Spectrum of MGN 
HPLC method development 
The aqueous phase for the present method development was 
HPLC grade water. The aqueous phase is also consisting of 
0.5% Triethylamine as an ion pairing reagent. The pH of the 
aqueous phase was adjusted with Ortho phosphoric acid and 
maintained at pH 5.0. 
Preparation of standard stock solution of MGN 
10mg of MGN was precisely weighed and dispensed to100ml 
volumetric flask containing few ml of mobile phase 
(Methanol 70: Water 30 at pH 5.0adjusted with OPA). The 
volume was made up to the mark using mobile phase slowly 
and from side to side mild wobbly to make up the 
substantial solution of 100μg/ml. This solution was ultra-
sonicated for 30min in three cycles each of 10 min. 
Furthermore, it was the filtered through 0.45μ membrane 
filter in order to take away minute particles if any. 
Preparation of working solution of MGN 
Aliquot of 1.0ml of standard stock solution of MGN was 
withdrawn by means of micropipette and diluted to 10.0ml 
with mobile phase (Methanol 70: Water 30 at pH 
5.0adjusted with OPA) to make the resultant solution of 
10μg/ml. This solution was ultra-sonicated for 30 min in 
three cycles each of 10 min. Also, it was then filtered through 
0.45μ membrane syringe filter and filled in HPLC vials for 
injection. This solution was then used for supplementary 
study. 
Selection of mobile phase 
To begin with mobile phase composition of Methanol: Water 
50:50 was selected for RP-HPLC trial runs. The separation 
carried out on C18stationary phase (4.6mm x 250mm, 5µ 
particle size). The results obtained were evaluated for 
retention time, peak area, no. of theoretical plates and tailing 
factor. The conditions for trial runs were as given in Table 1 
below. 
An additional trial run was executed with composition of 
methanol: water in the ratio of 70:30 at pH 5.0 adjusted with 
OPA at flow rate of 1ml/min. The detector was set at 243nm. 
The chromatogram obtained was evaluated for retention 
time, peak area, no. of theoretical plates and tailing factor. 
Table 1 Chromatographic conditions for trial runs 
Sr. 
no. 
Mobile Phase Flow rate Wavelength 
1 Methanol: Water (50:50) 1ml/min 243nm 
2 Acetonitrile: Water 
(50:50) 
1ml/min 243nm 
3 Methanol: Water (70:30) 
at pH 5.0 adjusted with 
OPA 
1ml/min 243nm 
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System suitability testing 
The system suitability testing was planned to ensure the 
consistency of the system for evaluation of MGN. The study 
was proposed with 10μg/ml working solution as prepared in 
process written in section 6.2.1.4. This solution was injected 
to set chromatographic conditions as given in Table 3. to 
evidence the chromatogram for MGN. The following 
chromatogram was integrated to get retention time, peak 
area, tailing factor and number of theoretical plates for MGN. 
Table 2. Table for chromatographic conditions set for 
the experiment 
Chromatographic Conditions 
Column Phenomenex C18 (250mm×4.6mm), 5μm id 
Mobile phase METHANOL :  WATER 
70: 30 at pH 5.0 adjusted with OPA 
Detection 
Wavelength 
243 nm 
Flow rate 1.0 ml/min 
Temperature Ambient 
Sample size 10.0μl 
Run Time 6 min 
 
HPLC method validation 
Linearity and Range:   Volume of standard stock solution 
(100μg/ml)of MGN equivalent to 1.0, 2.0, 3.0, 4.0, 5.0 and 
6.0ml was pipette out using micro-pipette and transferred to 
six different 10ml volumetric flasks. The aliquot of each 
volumetric flask was diluted up to 10ml using the mobile 
phase to attain the consequent solutions of 10, 20, 30, 40, 50, 
and 60μg/mlin that order. Each of this solution was injected 
to the given chromatographic conditions and 
chromatograms were recorded. The same function was 
persistent three times for all standard solutions prepared to 
study linearity. 
Precision:  Precision of the method was studied at three 
points across the range for MGN. This was performed by 
setting three quality control standards for MGN in the given 
series of 10 to 60μg/ml. Precision experiment was 
performed to study two dissimilar parameters viz. 
repeatability and intermediate precision. 
Accuracy:  % Accuracy was determined from the particulars 
obtained for precision study. At this point it was determined 
from the observations of mean peak area obtained in the 
case of three QC standards of MGN defined for precision 
study.   
Robustness:  In Robustness, the system parameters like 
organic concentration of the mobile phase (Methanol) and 
flow rate were varied as per Table 10 & 11 The 10μg/ml 
concentration standard solution of MGN was selected for 
this study and it was kept constant throughout all system 
parameters varied. The preferred concentration (10μg/ml) 
was injected to given chromatographic conditions three 
times at each level of change and chromatograms recorded. 
From the chromatograms acquired mean peak area was 
determined in all measurements made. 
%Recovery:   
 Preparation of stock from API:  
10mg of MGN (API) was precisely weighed and transferred 
to 100ml volumetric flask containing few ml of mobile 
phase and volume was made up to the mark (100ml) using 
mobile phase (Methanol 70: Water 30 at pH 5.0adjusted 
with OPA) to obtain final concentration standard stock 
solution of MGN 100μg/ml. The following solution was 
filtered through 0.45μ membrane filter and ultra-sonicated 
for 30 min in three cycles each of 10 min. 
 Preparation of standard stock solution from dosage 
form 
Twenty tablets (Label claim 50mg of Mirabegron (OAB-F) 
Alembic Pharmaceuticals ltd) were weighed, triturated to 
obtain powder and average weight of powder was 
determined. Powder equivalent to 10mg was transferred to 
100ml of mobile phase to attain the main stock solution of 
MGN100μg/ml. The substantial solution was filtered 
through 0.45μ membrane filter and ultra-sonicated for 
30min in three cycles each of 10 min. From the main stock 
sample solution of MGN aliquots of 0.8, 1.0 and 1.2ml were 
pipette out using micro pipette in three different 10ml 
volumetric flasks and the solution of each of these flasks 
was diluted up to 10ml using mobile phase to obtain 
resultant sample solutions of 8, 10, 12μg/ml respectively. 
 Preparation of test solution for % recovery by spike 
method 
10μg/ml solution (prepared previously) of MGN (API) was 
spiked into each of above sample solutions of MGN viz. 8, 10 
and 12μg/ml to obtain test solutions at 80%, 100% and 
120%likewise. Each of these three level test solutions of 
MGN was injected in triplicate to the given chromatographic 
conditions and mean peak area for each level was 
determined. 
Limit of Detection (LOD) and Limit of Quantitation 
(LOQ):  The  LOD  and  LOQ  were  calculated  from  the  
slope(s)  of  the calibration plot and the standard deviation 
(SD) of thepeak areas using the formulae LOD = 3.3 σ/s and 
LOQ = 10σ/s. The results were given in Table 
RESULTS AND DISCUSSION 
Results of  system  suitability  study  are  summarized  in 
Table 1. Six consecutive injections of the Standard solution 
showed uniform retention time, theoretical plate count, 
tailing factor and  resolution  For  both  the  drugs  which  
indicate  a  good system for analysis.
 
Table 3. Observation table for SST of MGN 
Sr. 
No. 
Parameter Mean observations SD %RSD Acceptance 
criteria 
 
 
Inference 
1 Peak Area 277776 5015.53 1.81 < 2  Pass 
2 Retention time 2.58 0.005 0.19 > 0.5  Pass 
3 Number of Theoretical 
plates* 
6736 -- -- > 2000  Pass 
4 Tailing factor* 1.12 -- -- < 2  Pass 
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Figure 3. Chromatogram of MGN obtained in system suitability experiment 
 
Linearity and Range: 
Table 4 Observation table for results obtained in 
linearity study 
Sr. No. Conc. of MGN(μg/ml) Mean Peak Area* 
1 10 282671 
2 20 574102 
3 30 852123 
4 40 1111207 
5 50 1420554 
6 60 1732810 
 
 
Figure 4 Calibration Curve of Mirabegron showing linear 
relationship between two variables
 
 
Figure 5 Representative chromatogram in linearity study observed at 10ppm 
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Table 5. Peak Table for Linearity experiment at 10ppm  
Inj. No. Name Retention Time(min) Area No. of Theoretical Plates Tailing Factor 
1. MIRABEGRAN 2.66 291261 5339 1.12 
 
Precision 
Table 6. Observations noted for intra and inter day precision of MGN 
Conc. 
(μg/ml) 
Intra-day precision (Repeatability) Inter-day precision (Intermediate Precision) 
 Mean peak area ± SD % RSD Inference Mean peak area ± SD % RSD Inference 
(<2%RSD) 
15 389077±7621.57 1.96 Passed 388012±7358.17 1.90 Passed 
35 984755±6751.46 0.69 Passed 980868±9024.61 0.92 Passed 
55 1512113±9789.95 0.65 Passed 1513161±15884.81 1.05 Passed 
 
 
Figure 6. Chromatogram obtained for MGN at 15ppm Intra-day precision 
 
Table 7. Peak Table for Intra-day precision experiment at 15ppm  
Inj. 
No. 
Name Retention Time 
(min) 
Area No. of Theoretical Plates Tailing Factor 
1. MIRABEGRAN 2.67 181367 5394 1.10 
 
% Accuracy 
Table 8. Percent accuracy determined from the data obtained for intermediate precision experiment 
Sr. 
No. 
Conc. 
(μg/ml) 
Mean Peak 
Area* 
Mean Measured Conc. 
(μg/ml) 
% 
Accuracy 
Inference (Stad. For MGN 95-
105% w/w) 
1 15 388012.00 13.84 92.26 Failed 
2 35 980868.00 34.49 98.54 Passed 
3 55 1513161.00 53.03 96.41 Passed 
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Figure 7. Chromatogram observed for percent accuracy at 35p 
 
Table 9.  Peak Table for percent accuracy experiment at 35ppm 
Inj. No. Name Retention Time 
(min) 
Area No. of Theoretical Plates Tailing Factor 
1. MIRABEGRAN 2.66 978236 4495 1.11 
 
Robustness 
Table 10.  Observations of robustness expt. for variation in methanol concentration 
Methanol 
Concentration (%) 
Standard Conc. 
(μg/ml) 
Mean 
peak area* 
Mean measured conc. 
(μg/ml) 
% 
Assay 
Inference (Stad. For MGN 
95-105% w/w) 
70 10 282671 10.17 101.70 Passed 
72 10 281543 10.13 101.31 Passed 
68 10 284374 10.23 102.30 Passed 
 
Table 11.  Observations of robustness expt. for variation in flow rate per min of mobile phase 
Flow Rate 
(ml/min) 
Standard 
Conc. (μg/ml) 
Mean peak 
area* 
Mean measured conc. 
(μg/ml) 
% Assay Inference (Stad. For MGN 95-
105% w/w) 
1.0 10 282671 10.17 101.70 Passed 
0.9 10 280453 10.09 100.93 Passed 
1.1 10 281736 10.14 101.38 Passed 
 
% Recovery: 
Table 12. Observation table for percent recovery study of MGN at three levels viz 80, 100 and 120% 
% 
Recovery 
Level 
Conc. Of 
standard spiked 
(μg/ml) 
Conc. of 
sample 
(μg/ml) 
Mean peak Area 
of sample conc.* 
Amount 
recovered# 
(μg/ml) 
% Recovey 
Inference 
(Std. MGN 
assay 95-
105% 
w/w) 
80 10 8 232692 8.43 104.65 Passed 
100 10 10 284592 10.24 102.39 Passed 
120 10 12 338602 12.12 101.52 Passed 
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Figure 8. Chromatogram obtained for Mirabegron (MGN) at 100% recovery level 
Table 13. Peak Table for recovery experiment at 100% level 
Inj. No. Name Retention Time(min) Area No. of Theoretical Plates Tailing Factor 
1. MIRABEGRAN 2.65 565181 4384 1.15 
 
LOD and LOQ :         
Table No 14. Results of LOD& LOQ 
Standard Drug Solution LOD (μg/ml) LOQ (μg/ml) 
Mirabegron (MGN) 2.07 6.28 
 
 
SUMMARY AND CONCLUSION 
The proposed study was planned to develop RP-HPLC 
method for quantitative estimation of Mirabegron (MGN) as 
API and to ascertain its application for estimation of MGN in 
finished product formulation (marketed tablet dosage form). 
We have fruitfully developed the RP-HPLC method 
estimation of MGN as API. The chromatographic conditions 
found an appropriate for the projected method were as 
herein below. Also, the system was found to be an 
appropriate with the following chromatographic conditions. 
Chromatographic Conditions 
Column Phenomenex C18 (250mm×4.6mm), 5μm id 
Mobile phase Methanol 70: Water 30 at pH 5.0 adjusted 
with OPA 
Detection 
Wavelength 
243 nm 
Flow rate 1.0 ml/min 
Temperature Ambient 
Sample size 10μl 
Run Time 6 min 
 
The developed and optimized method was then subjected to 
method validation as per ICH Q2R1 guideline for the 
parameters like linearity, range, precision, accuracy, 
robustness, detection limit, quantitation limit etc. The 
linearity was established by measuring a series of standard 
solutions of MGN and found in the range of 10-60μg/ml. The 
calibration curve developed suggested linear relationship 
amongst concentration of MGN and observed response 
(mean peak area for MGN) with correlation coefficient of 
0.9991. The regression equation obtained was y = 28712x – 
9335.7. 
Precision of the method was studied at three levels across 
the range observed in linearity study. Three QC standards 
were defined viz. 15, 35 and 55μg/ml for this study. 
Precision was performed to ascertain the repeatability and 
intermediate precision. The results obtained showed %RSD 
for repeatability and intermediate precision were in the 
range of 0.65 to 1.96 and 0.92 to 1.90in that order. Results 
observed for %RSD in both (repeatability and intermediate 
precision) cases were less than 2%, hence, the method was 
found to be precise. % Accuracy was determined from the 
data of precision study indicated the %assay in the range of 
92.26 to 98.54% w/w of MGN. 
The robustness of the method was studied by purposeful 
difference in method parameters like organic concentration 
(Methanol) and flow rate. The results observed for organic 
concentration variation and flow rate change were in the 
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range of 101.31-102.30 and 100.93-101.70% w/w 
respectively.           
The applicability of the method was studied in tablet dosage 
form of Mirabegron. The results obtained for percent 
recovery study were in the range of 101.52 to 104.65% w/w 
for MGN. The results obtained in conformity with the 
prescribed limits for MGN. In addition, absence of an 
additional peak (s) in this study indicated that the method 
was specific for the determination of MGN in capsule dosage 
form.    
Detection and quantitation limit were determined from the 
standard error of calibration curve of MGN and found to be 
2.07 and 6.28μg/ml respectively. From the lower values of 
detection limit it was observed that method was responsive 
for determination of MGN. 
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